U.S. Consumer Finance Stock News

Why Union Pacific (UNP) Is On Investors’ Radar Today Union Pacific (UNP) has drawn attention after recent share moves, with the stock showing mixed returns over the past week, month, and past 3 months while trading around $229.49 at the latest close. See our latest analysis for Union Pacific. At around $229.49, Union Pacific’s recent share price return has been soft over the past month, although its 1 year total shareholder return of 0.30% and 3 year total shareholder return of 18.00% suggest...

Rigel Pharmaceuticals (RIGL) has drawn fresh attention after launching a Phase 1b/2 trial combining REZLIDHIA with other therapies for acute myeloid leukemia and issuing full year 2026 revenue guidance of US$275 million to US$290 million. See our latest analysis for Rigel Pharmaceuticals. Despite the latest clinical update and 2026 revenue guidance, Rigel Pharmaceuticals’ recent share price performance has cooled, with a 7 day share price return of 8.23% and a 30 day share price return of...

Mueller Water Products triggered by GARP screen Mueller Water Products (MWA) recently passed a Peter Lynch Growth at a Reasonable Price screen, highlighting a mix of earnings growth, PEG based valuation, financial strength, and return on equity that has caught investor attention. See our latest analysis for Mueller Water Products. The GARP trigger comes after a steady run, with a 7 day share price return of 4.24% and a 30 day share price return of 6.39% at a latest close of $26.31, while 1...

Glancy Prongay & Murray LLP has filed a securities class action in the Southern District of Ohio alleging Bath & Body Works misled investors between June 4, 2024 and November 19, 2025, following sharp year-over-year declines in earnings, multiple guidance cuts, and acknowledgment that recent growth initiatives failed to expand its customer base. The lawsuit arrives as Bath & Body Works is both closing more mall locations and refreshing product lines, underscoring the tension between...

If you are wondering whether CAVA Group at around US$72 a share is a bargain or already pricing in a lot of optimism, you are not alone. The stock has returned 1.7% over the last 7 days and 35.7% over the last 30 days, while the year to date return is 19.1% and the 1 year return is a 39.0% decline. Recent coverage has focused on CAVA Group as a newly public fast casual restaurant brand with strong consumer awareness, with attention on how quickly it is expanding its store base and scaling...

Earlier this month, Hankook Tire America Corp. opened the Hankook Tire Clinic Powered by Evernorth at its Clarksville, Tennessee plant, while The Cigna Group also renewed its multiyear sponsorship of Achilles International’s Freedom Team with nearly US$1.00 million committed over three years. Together, these initiatives highlight Cigna’s emphasis on integrated health services and visible community investment in veterans and athletes with disabilities, reinforcing its broader health-focused...

Private Bancorp of America (PBAM) has wrapped up FY 2025 with fourth quarter revenue of US$29.9 million and basic EPS of US$1.75, alongside trailing twelve month revenue of US$119.2 million and EPS of US$7.09. Over recent periods, the company has seen quarterly revenue move from US$26.8 million in Q3 2024 to just over US$30.5 million in Q2 2025, with quarterly EPS ranging from about US$1.64 to US$1.83 over that span. This sets a clear earnings base for investors to work from. With a trailing...

Biogen (BIIB) has come back into focus after the European Commission approved a high dose regimen of SPINRAZA for 5q spinal muscular atrophy, supported by Phase 2/3 DEVOTE trial results and a prior approval in Japan. See our latest analysis for Biogen. These SPINRAZA developments and Biogen's conference presence come after a choppy stretch, with a 7 day share price return of 12.37% decline and a 1 year total shareholder return of 16.98%. This suggests that longer term holders have fared...

If you are wondering whether InterDigital's share price still offers value at current levels, you are not alone. This article walks through what that price might imply about the stock. After a strong 81.7% return over the past year and a very large 3-year gain of about 4x, the stock has recently cooled, with a 0.1% 7-day slip, a 5.0% decline over 30 days, and a 5.4% fall year to date from a last close of US$308.76. Recent attention on InterDigital has been shaped by ongoing interest in...

Kosmos Energy recently reported operational progress, including completing a second Jubilee producer well in Ghana, securing license extensions for the Jubilee and TEN fields to 2040, and confirming that the Greater Tortue Ahmeyim LNG project reached nameplate capacity in December 2025. Together with a planned US$350 million senior secured bond issue to refinance nearer-term debt, these developments reshape Kosmos’ production profile, reserve life, and balance sheet flexibility for years...

If you are wondering whether D.R. Horton at around US$155 a share still offers value, you are not alone. That is exactly what this article will unpack. The stock has had mixed recent returns, with a 0.8% decline over the last 7 days, a 2.6% gain over 30 days, and returns of 7.0% year to date and 6.9% over the last year, on top of a 70.0% return over 3 years and 110.9% over 5 years. Recent coverage around large US homebuilders has focused on how investors are weighing long term housing demand...

J.B. Hunt Transport Services (JBHT) just wrapped up FY 2025 with fourth quarter revenue of US$3.1b and basic EPS of US$1.90, alongside net income of US$181.1m. The company has seen quarterly revenue move from US$3.1b in Q4 2024 to US$3.1b in Q4 2025, while basic EPS shifted from US$1.53 to US$1.90 over the same period. Trailing twelve month EPS stands at US$6.12 on revenue of US$12.0b. With net margin at 5.0% and slightly higher than last year, the focus this season is on how efficiently...

If you are wondering whether Doximity is attractively priced at its current level or if the market is overlooking something in plain sight, this article is for you. The stock is at US$41.26 after a 5.8% decline over the last 7 days, a 5.6% decline over 30 days and a 4.7% decline year to date, while the 3 year return sits at 27.8% and the 1 year return at a 23.2% decline. Recent coverage around Doximity has focused on its role as a digital platform for medical professionals and how that...

Mountain Pacific Bancorp (MPCB) just wrapped up FY 2025 with fourth quarter revenue of about US$10.0 million and net income of US$3.1 million, set against a trailing twelve month total of US$38.7 million in revenue and US$13.1 million in net income. The company has seen revenue move from US$28.7 million to US$38.7 million on a trailing basis, while trailing earnings growth of 67.1% and a net profit margin of 33.9% frame a results season in which profitability and efficiency are front and...

Why this new drug delivery alliance matters for Stevanato Group Datwyler’s new collaboration with LTS Device Technologies and Stevanato Group (STVN) centers on large volume, on body subcutaneous drug delivery, targeting in home use and the growing role of biologic therapies. See our latest analysis for Stevanato Group. Stevanato Group’s latest news on large volume drug delivery comes after a tougher period for the stock, with a 19.19% decline in the 3 month share price return and a 13.33%...

Earlier this month, American Financial Group, Inc. declared a regular cash dividend of US$0.88 per common share, payable on January 27, 2026, to shareholders of record as of January 15, 2026. Wells Fargo has now initiated coverage of American Financial Group with an Overweight rating, highlighting expectations for better 2026 growth supported by the company’s relatively low property exposure and focus on maintaining stable margins and return on equity. We’ll now examine how Wells Fargo’s...

Niagen Bioscience (NAGE) has drawn fresh attention after announcing a partnership with Truemed that lets qualified customers buy Tru Niagen using Health Savings Account and Flexible Spending Account funds on its direct website. See our latest analysis for Niagen Bioscience. That HSA and FSA payment update arrives after a period of softer momentum, with a 90 day share price return of a 15.55% decline and a year to date share price return of a 0.96% decline, even as the three year total...

If you are wondering whether SouthState Bank's share price reflects its true worth, you are not alone. This article walks through what the current market price might be implying about value. The stock last closed at US$98.43, with returns of 0.8% over the past week, 0.8% over the last month, 4.5% year to date and 1.2% over the past year, while the 3 year and 5 year returns sit at 37.1% and 40.1% respectively. Recent moves in U.S. regional bank shares have kept investor attention on balance...

Axogen (AXGN) is back in focus after securing FDA approval and a biologics license for its Avance Nerve Graft, alongside preliminary 2025 guidance that indicates higher fourth quarter and full year revenue. See our latest analysis for Axogen. The FDA approval and updated 2025 revenue guidance come after a sharp shift in sentiment, with a 90-day share price return of 86.98% and a 1-year total shareholder return of 71.48% pointing to building momentum despite recent short term volatility. If...

In its latest reported quarter, Freshpet delivered a 14% year-over-year revenue increase and surpassed analysts’ expectations on both revenue and earnings, with leadership emphasizing category-leading growth and strong financial and operational performance. This combination of outperformance against estimates and management’s confidence in the business highlights how Freshpet’s recent execution may be reinforcing its longer-term margin and growth ambitions. We’ll now explore how Freshpet’s...

Paycom Software: Recent Returns and Business Snapshot Paycom Software (PAYC) has been under pressure recently, with the stock showing negative returns over the past week, month and past 3 months. This performance has prompted some investors to reassess its current valuation. See our latest analysis for Paycom Software. At a share price of US$148.41, Paycom’s recent 11% 30 day share price decline and 26% 90 day share price decline sit alongside a 1 year total shareholder return decline of 29%...

In early January 2026, Xeris Biopharma Holdings, Inc. raised its full-year 2025 revenue guidance to approximately US$292 million, above its prior US$285–US$290 million range, signaling better-than-planned top-line performance. This upward revision suggests the company’s commercial portfolio is gaining more traction than initially forecast, reshaping how investors may assess its revenue potential and operational progress. We’ll now examine how this higher 2025 revenue guidance intersects...

In recent days, Venture Global has drawn attention after revising its adjusted EBITDA outlook for late 2025 while continuing to export 128 cargos of LNG during a period of heightened winter energy demand. At the same time, concerns around eroding margins, a complex capital structure, and litigation risks have sharpened the focus on how much value ultimately reaches common shareholders. With these developments and strong winter-driven LNG exports in mind, we’ll now examine how they shape...

NioCorp Developments Ltd. recently reported final assay results from its 2025 drilling campaign at the Elk Creek Critical Minerals Project in Nebraska, which aligned with internal expectations and supported confidence in mineralization continuity, while also announcing progress on development funding, land acquisition, and scandium alloy capabilities. Although these assay results are not yet classified as reserves or resources under SEC or Canadian standards, the combination of U.S...